eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
2/2021
vol. 38
 
Share:
Send email
Share:
abstract:
Original paper

Safety of bronchodilator reversibility test in elderly subjects: a prospective study

Anna Dor-Wojnarowska
1
,
Anna Parużyńska
2
,
Aleksandra Kulczak
2
,
Marta Majewska-Pulsakowska
1
,
Małgorzata Szymala-Pędzik
2
,
Zbigniew Machaj
2
,
Małgorzata Sobieszczańska
2
,
Małgorzata Poręba
3

  1. Department and Clinic of Internal Medicine and Allergology, Wroclaw Medical University, Wroclaw, Poland
  2. Department and Clinic of Geriatrics, Wroclaw Medical University, Wroclaw, Poland
  3. Department of Pathophysiology, Wroclaw Medical University, Wroclaw, Poland
Adv Dermatol Allergol 2021; XXXVIII (2): 256-261
DOI: https://doi.org/10.5114/ada.2020.92515
Online publish date: 2020/02/01
View full text Get citation
 
Introduction
The reversibility test measures an increase in ventilation parameters after the administration of 400 mg of a short-acting b-agonist (SABA). It is worth noting that a typical dosage, applied as a rescue medicine for bronchospastic dyspnoea, is significantly less, i.e., 100–200 mg.

Aim
To assess the effects of inhaled 400 mg fenoterol (in the bronchodilator reversibility test) on the heart rate and the development of tachyarrhythmias in subjects aged 65 and above.

Material and methods
A total of 53 subjects (45 women) aged 77; 68–82 (median; interquartile range) in stable clinical condition were included in the study. Data including medical history, physical examinations, blood biochemistry, chest X-ray, 12-lead electrocardiogram, 24-hour Holter ECG monitoring, bronchodilator test, and echocardiography were obtained. During the Holter ECG monitoring, the bronchodilator test using 400 mg fenoterol (Berotec pMDI) was performed.

Results
A slight but statistically significant (p = 0.02) increase in heart rate from 71 to 75 per min (median) was noted after the administration of fenoterol. No statistically significant differences were found in the number of extrasystolic beats of either supraventricular (p = 0.42) or ventricular origin (p = 0.50). In addition, the subjects did not show any potentially dangerous arrhythmias or significant signs of coronary artery disease. However, there was a significant increase in the number of supraventricular beats in the subjects who were not taking β-blockers.

Conclusions
The use of 400 mg fenoterol in a bronchodilator reversibility test in elderly subjects does not entail any significant cardiovascular risk.

keywords:

24-hour Holter ECG monitoring, bronchodilator test, elderly subjects
FEATURED PRODUCTS
BOOKS
• Atopowe Zapalenie Skóry • Choroby alergiczne w praktyce lekarza rodzinnego • Alergologia – kompendium
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.